DK0499920T3 - Lacidipin til behandling af arteriosclerosis - Google Patents

Lacidipin til behandling af arteriosclerosis

Info

Publication number
DK0499920T3
DK0499920T3 DK92102146.5T DK92102146T DK0499920T3 DK 0499920 T3 DK0499920 T3 DK 0499920T3 DK 92102146 T DK92102146 T DK 92102146T DK 0499920 T3 DK0499920 T3 DK 0499920T3
Authority
DK
Denmark
Prior art keywords
lacidipine
arteriosclerosis
treatment
pyridinedicarboyxlic
dimethylethoxy
Prior art date
Application number
DK92102146.5T
Other languages
English (en)
Inventor
Giovanni Gaviraghi
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Application granted granted Critical
Publication of DK0499920T3 publication Critical patent/DK0499920T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK92102146.5T 1991-02-13 1992-02-08 Lacidipin til behandling af arteriosclerosis DK0499920T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI910359A IT1244728B (it) 1991-02-13 1991-02-13 Impiego medicamentoso di derivati diidropiridinici

Publications (1)

Publication Number Publication Date
DK0499920T3 true DK0499920T3 (da) 1998-01-26

Family

ID=11358541

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92102146.5T DK0499920T3 (da) 1991-02-13 1992-02-08 Lacidipin til behandling af arteriosclerosis

Country Status (24)

Country Link
US (1) US5455257A (da)
EP (2) EP0576433A1 (da)
JP (1) JP2996725B2 (da)
KR (1) KR100188171B1 (da)
AT (1) ATE157004T1 (da)
AU (1) AU646929B2 (da)
CA (1) CA2103805C (da)
CZ (1) CZ281760B6 (da)
DE (1) DE69221649T2 (da)
DK (1) DK0499920T3 (da)
ES (1) ES2106098T3 (da)
GR (1) GR3024661T3 (da)
HK (1) HK1009585A1 (da)
IE (1) IE920453A1 (da)
IL (1) IL100928A (da)
IT (1) IT1244728B (da)
MX (1) MX9200600A (da)
NO (1) NO303713B1 (da)
PH (1) PH30130A (da)
RU (1) RU2136279C1 (da)
SG (1) SG59972A1 (da)
UA (1) UA27780C2 (da)
WO (1) WO1992014460A1 (da)
ZA (1) ZA921006B (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1868577A4 (en) * 2005-04-15 2009-12-09 Reddys Lab Inc Dr Lacidipine PARTICLE
WO2007096694A1 (es) * 2006-02-22 2007-08-30 Ramiro Vergara Asociacion de principios activos neuroactivadores

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS597163A (ja) * 1982-07-02 1984-01-14 Yamanouchi Pharmaceut Co Ltd 抗動脈硬化剤
NZ212895A (en) * 1984-08-22 1988-07-28 Glaxo Spa 1,4-dihydropyridine derivatives and pharmaceutical compositions
GB8431119D0 (en) * 1984-12-10 1985-01-16 Fujisawa Pharmaceutical Co Anti-arteriosclerotic composition

Also Published As

Publication number Publication date
EP0499920B1 (en) 1997-08-20
GR3024661T3 (en) 1997-12-31
CZ281760B6 (cs) 1997-01-15
WO1992014460A1 (en) 1992-09-03
ATE157004T1 (de) 1997-09-15
AU646929B2 (en) 1994-03-10
AU1223192A (en) 1992-09-15
MX9200600A (es) 1992-10-30
DE69221649D1 (de) 1997-09-25
CA2103805A1 (en) 1992-08-14
ITMI910359A1 (it) 1992-08-13
UA27780C2 (uk) 2000-10-16
JPH06505002A (ja) 1994-06-09
EP0499920A1 (en) 1992-08-26
DE69221649T2 (de) 1997-12-11
ZA921006B (en) 1992-12-30
RU2136279C1 (ru) 1999-09-10
ES2106098T3 (es) 1997-11-01
US5455257A (en) 1995-10-03
IE920453A1 (en) 1992-08-12
JP2996725B2 (ja) 2000-01-11
NO932874D0 (no) 1993-08-12
NO932874L (no) 1993-08-12
PH30130A (en) 1997-01-21
CZ165093A3 (en) 1994-03-16
SG59972A1 (en) 1999-02-22
CA2103805C (en) 2002-09-17
IT1244728B (it) 1994-08-08
EP0576433A1 (en) 1994-01-05
NO303713B1 (no) 1998-08-24
HK1009585A1 (en) 1999-06-04
ITMI910359A0 (it) 1991-02-13
KR100188171B1 (en) 1999-06-01
IL100928A (en) 1997-02-18

Similar Documents

Publication Publication Date Title
DE69226449D1 (de) 2-(2,6-difluorphenyl)-4-(2-ethoxy-4-tert-butylphenyl)-2-axazoline
FR2663836B1 (fr) Implant orthopedique ou dentaire multibloc.
DE69324036D1 (de) Dentales implantat
DE69620306D1 (de) 4-(.Alpha.-hydroxy-.alpha.-aryl-alkylcarbonylamino)-Piperidine zur Behandlung und Prophylaxe von Erkrankungen der Harnwege
DE69224080D1 (de) Verwendung von nsaid zur behandlung von demenz
DE10199034I2 (de) Fungizide oxazolidinone.
ATE253361T1 (de) Mittel zur gesteuerten freisetzung von paroxetin
DK0634175T3 (da) Farmaceutisk kombination, der indeholder en hæmmer af renin-angiotensin-systemet og en endothelin-antagonist
DK0604183T3 (da) HIV-protease-inhibitorer anvendelige i behandlingen af AIDS
DE69300062D1 (de) Verfahren zur Herstellung von N-Methoxyderivate von 4-Hydroxy-2,2,6,6-Tetramethylpiperidin und 2,2,6,6-Tetramethyl-4-Piperidon.
PT790236E (pt) Pro-farmacos de 5-(2-(4-(1,2-benzisotiazol-3-il)-1-piperazinil)-etil-6-cloro-1,3-di-hidro-2h-indol-2-ona
DK0499920T3 (da) Lacidipin til behandling af arteriosclerosis
DE69231883D1 (de) 4-(1,1-Dialkoxycarbonyl-Alkyl)Azetidin-2-on-Derivate zur Herstellung von 4-(1-Carboxy-Alkyl)Azetidin-2-on-Derivaten
EE04235B1 (et) Toimeainete, nimelt tetrahüdropüridiinide ja atsetüülkoliinesteraasi inhibiitorite, kombinatsioon Alzheimeri tõve tüüpi seniildementsuse raviks
DE69625069D1 (de) Insektizide von n-(substituiertes arylmethyl)-4-(bis (substituiertes phenyl oder pyridyl)methyl)-piperidin.
RU93054780A (ru) Применение лацидипина для лечения артериосклероза
FR2684540B1 (fr) Implant dentaire.
ITRM910211A0 (it) Impianto dentale endosseo.
NO953322L (no) Anvendelse av 1,4-dihydropyridin-3,5-dikarboksylsyreestere som legemidler
DE69215106D1 (de) Zahnimplantat
ATE122352T1 (de) 3-(3-ethyl-1,2,4-oxadiazol-5-yl)-1- azabicycloheptan, verfahren zu seiner herstellung und dieses enthaltende pharmazeutische zubereitungen.
DZ1831A1 (fr) Isopropyl 2-méthoxyéthyl 4-(2-chloro-3-cyano-phényl)-1,4-dihydro 2,6-diméthyl-pyridine 3,5-dicarboxylate.
FR2707867B1 (fr) Implants dentaires.
ES1023915Y (es) Implante dental.
DE69616484D1 (de) Verwendung vom 3-Alpha-Hydroxy-5Alpha-Androsta-16-ene als Arzneimittel